이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

비허혈성 확장성 심근병증 환자에서 동종 MSC의 경내심막 주사 (DCMII)

2026년 9월 28일 업데이트: Joshua M Hare

비허혈성 확장성 심근병증 환자에서 위약과 동종이계 MSC의 심내막 경유 주사의 비교 효능 및 안전성에 대한 제IIB상 무작위, 위약 대조, 다기관 연구

The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy.

연구 개요

연구 유형

중재적

등록 (실제)

107

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • Stanford, California, 미국, 94304
        • Stanford University
    • Florida
      • Miami, Florida, 미국, 33136
        • University of Miami Miller School of Medicine
    • Kentucky
      • Louisville, Kentucky, 미국, 40202
        • University of Louisville
    • Texas
      • Houston, Texas, 미국, 77030
        • Texas Heart Institute

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Men and women aged 18 to 80 years (inclusive) at the time of signing the informed consent form.
  2. Diagnosis of NIDCM with left ventricular ejection fraction ≤45%.
  3. Appropriate guideline-directed optimal medical therapy for non-ischemic cardiomyopathy. At a minimum, subjects must be on beta blockers and angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) or Angiotensin Receptor Neprilysin Inhibitors (ARNI) or have appropriate medical indication precluding use of one or both of these agents. Subjects must be on a stable regimen for at least 30 days prior to the procedure. Dose titration is allowed.
  4. Be a candidate for cardiac catheterization*
  5. Be willing to undergo DNA test.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Be eligible for or require standard-of-care surgical or percutaneous intervention for the treatment of non-ischemic dilated cardiomyopathy

  2. Clinical manifestation of coronary artery disease (CAD) (e.g., chest pain and concomitant clinical findings such as electrocardiogram changes suggestive of coronary ischemia, myocardial infarction) or evidence of endocardial or transmural scar on cardiac MRI suggestive of undiagnosed CAD or history of percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG). Be indicated for or require coronary artery revascularization

  3. Documented presence of epicardial stenosis of 70% or greater in one or more major epicardial coronary arteries

  4. Valvular heart disease including 1) aortic valve prosthesis, mechanical mitral valve, and mitral valve clip; 2) severe aortic valve insufficiency/regurgitation within 12 months of consent*

  5. Aortic stenosis with valve area ≤ 1.5cm2*

  6. Cardiomyopathy due to acute Post-partum (within 6 months), Non-compaction*, or Hypertrophic* cardiomyopathy

  7. Cardiomyopathy due to known toxin (e.g amyloid) Note: anthracycline induced cardiomyopathy will be allowed

  8. QTc interval > 550 ms on baseline electrocardiogram (ECG) (note: QTc interval is the interval between the start of the Q wave and the end of the T wave in the heart's electrical cycle)

  9. Automated Implantable Cardioverter Defibrillator (AICD) appropriate firing or anti tachycardia pacing for ventricular tachycardia or ventricular fibrillation within 30 days prior to consent

  10. Have an estimated baseline glomerular filtration rate below the clinical site's institutional cutoff

  11. A hematologic abnormality during baseline testing as evidenced by hemoglobin < 9 g/dl; hematocrit < 30%; absolute neutrophil count < 2,000 or total WBC count more than 2 times upper limit of normal; or platelet values < 100,000/ul

  12. Have liver dysfunction, as evidenced by enzymes Aspartate Transaminase Enzyme (AST) and Alanine Aminotransferase Enzyme (ALT) greater than three times the ULN

  13. Have a bleeding diathesis or coagulopathy (International Normalised Ratio (INR) > 1.5), cannot be withdrawn from anticoagulation therapy, or will refuse blood transfusions

  14. Be a solid organ transplant recipient. This does not include prior cell based therapy (>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting.

  15. Have a history of organ or cell transplant rejection

  16. Have a clinical history of malignancy within the past 12 months (i.e., subjects with prior malignancy must be disease free for 12 months), except curatively treated basal cell or squamous cell carcinoma or cervical carcinoma

  17. Drug and/or alcohol abuse or dependence within the past 9 months

  18. Be serum positive for HIV, hepatitis B surface antigen, or viremic hepatitis C

  19. Documented presence of a known Left Ventricular (LV) thrombus, aortic dissection, or aortic aneurysm. (Refer to "Guidance to the PI" section with regards to LV thrombus, below)*

  20. Blood glucose levels (HbA1c) >10%

  21. Severe radiographic contrast allergy

  22. Known history of anaphylactic reaction to penicillin or streptomycin

  23. Hypersensitivity to dimethyl sulfoxide (DMSO)

  24. Non-cardiac condition with life expectancy < 1 year

  25. Acute stroke or transient ischemic attack within 3 months of enrollment

  26. Be pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods

  27. Pacemaker-dependence with an Implantable Cardioverter Defibrillator (ICD) (Note: pacemaker-dependent candidates without an ICD are not excluded)

  28. Presence of a pacemaker and/or ICD generator with any of the following limitations/conditions:

    • manufactured before the year 2000
    • leads implanted < 6 weeks prior to consent
    • non-transvenous epicardial or abandoned leads
    • subcutaneous ICDs
    • leadless pacemakers
  29. A cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to consent

  30. Other MRI contraindications (e.g. subject body habitus incompatible with MRI)

  31. Need for advanced heart failure therapy (e.g. IV inotropes)

  32. Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial

  33. Any other condition that in the judgment of the Investigator would be a contraindication to enrollment or follow-up

(*) Applies to subjects receiving product via transendocardial administration only

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: Genotype A administered with placebo Group

Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the placebo group will receive the placebo intervention.

Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)

실험적: Genotype A administered with hMSC Group

Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the treatment group will receive the hMSC intervention.

allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).

위약 비교기: Genotype B administered with placebo Group

Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the placebo group will receive the placebo intervention.

Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)

실험적: Genotype B administered with hMSC Group

Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the treatment group will receive the hMSC intervention.

allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).

위약 비교기: Genotype C administered with placebo Group

Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the placebo group will receive the placebo intervention.

Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)

실험적: Genotype C administered with hMSC Group

Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the treatment group will receive the hMSC intervention.

allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in LVEF
기간: Baseline, 12 months

Change in Left Ventricular Ejection Fraction (LVEF) as assessed via cardiac Magnetic Resonance Imaging (MRI)

Baseline, 12 months

2차 결과 측정

결과 측정
측정값 설명
기간
Change in global ventricular strain
기간: Baseline, 12 months

Change in global ventricular strain as assessed via cardiac Harmonic Phase (HARP) MRI

Baseline, 12 months
Change in left regional strain
기간: Baseline, 12 months

Change in regional ventricular strain as assessed via cardiac HARP MRI

Baseline, 12 months
Left ventricular function concordance
기간: 12 months

The left ventricular function concordance will be measured as the Number of individuals who experienced an increase in left ventricular ejection fraction (LVEF) and a simultaneous decrease in both left ventricular end systolic volume index (LVESVI) and left ventricular end diastolic volume index (LVEDVI)

12 months
Change in LVEDVI
기간: Baseline, 12 months

Change in left ventricular end diastolic index (LVEDVI) as assessed via cardiac MRI

Baseline, 12 months
Change in LVESVI
기간: Baseline, 12 months

Change in left ventricular end systolic index (LVESVI) as assessed via cardiac MRI

Baseline, 12 months
Change in Maximal oxygen consumption (peak VO2)
기간: Baseline, 12 months

Change in maximal oxygen consumption (peak VO2) as assessed via treadmill

Baseline, 12 months
Change in Exercise tolerance
기간: Baseline, 12 months

Change in exercise tolerance as assessed as the distance covered via the six-minute walk test

Baseline, 12 months
Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score
기간: Baseline, 12 months

Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a 21-item questionnaire with a total score ranging from 0 to 105 with lower scores indicative of better outcome.

Baseline, 12 months
Change in New York Heart Association (NYHA) Class
기간: Baseline, 12 months

NYHA Classifications of heart failure are as follows: Class I (no limitations); Class II (mild symptoms); Class III (marked limitations); Class IV (Severe limitations)

Baseline, 12 months
Percent change in flow mediated diameter
기간: Baseline, 12 months

Change in endothelial function will be reported as the percent change in flow mediated diameter assessed via flow mediated dilation (FMD).

Baseline, 12 months
Change in EPC-CFU
기간: Baseline, 12 months

Change in endothelial function will be reported as the change in Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood sample assay

Baseline, 12 months
Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)
기간: Baseline, 12 months

Change in NT-proBNP as assessed via blood draw

Baseline, 12 months
Incidence of MACE
기간: 12 months

Safety will be reported as the incidence of Major Adverse Cardiac Events (MACE) assessed by treating physician

12 months
Incidence of TE-SAEs
기간: Day 30

Safety will be reported as the incidence of Treatment Emergent Serious Adverse Events (TE-SAEs) assessed by treating physician

Day 30

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Joshua Hare, MD, University of Miami

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 5월 7일

기본 완료 (추정된)

2027년 4월 1일

연구 완료 (추정된)

2027년 4월 1일

연구 등록 날짜

최초 제출

2020년 7월 15일

QC 기준을 충족하는 최초 제출

2020년 7월 15일

처음 게시됨 (실제)

2020년 7월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 29일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 28일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 20200566
  • CDMRP-PR191597 (기타 보조금/기금 번호: US Department of Defense)
  • 20-02-134 (기타 식별자: BRANY IRB)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다